Multicenter phase II trial of temozolomide (TMZ) and rituximab (RIT) for recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor Consortium (NABTC) study 05-01.
L. Nayak
No relevant relationships to disclose
L. E. Abrey
Consultant or Advisory Role - Roche
J. Drappatz
No relevant relationships to disclose
M. R. Gilbert
Consultant or Advisory Role - Genentech; Sigma-Tau
Honoraria - Genentech; Merck; Sigma-Tau
Research Funding - Genentech; Merck
D. A. Reardon
No relevant relationships to disclose
K. Lamborn
No relevant relationships to disclose
P. Y. Wen
Research Funding - Merck
M. Prados
No relevant relationships to disclose
L. M. DeAngelis
Consultant or Advisory Role - Genentech
A. M. P. Omuro
Research Funding - Genentech; Schering-Plough